TSE:4523Pharmaceuticals
How Investors Are Reacting To Eisai (TSE:4523) Data Backing LEQEMBI’s Long-Term Real-World Use
Eisai and Biogen recently reported real-world data showing that most patients receiving intravenous lecanemab (LEQEMBI) for Alzheimer’s disease remained on therapy beyond 18 months, with adherence patterns broadly consistent with clinical trial dosing and minimal disruption from monitoring requirements.
The findings, together with long-term extension results indicating sustained cognitive benefit versus observational Alzheimer’s cohorts, strengthen the clinical and practical case for...